These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 8453706)
1. Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. Blum RH; Edmonson J; Ryan L; Pelletier L Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S238-40. PubMed ID: 8453706 [TBL] [Abstract][Full Text] [Related]
2. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY; J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494 [TBL] [Abstract][Full Text] [Related]
3. Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study. Budd GT; Metch B; Weiss SA; Weick JK; Fabian C; Stephens RL; Balcerzak SP Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S213-6. PubMed ID: 8453701 [TBL] [Abstract][Full Text] [Related]
4. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. Schütte J; Kellner R; Seeber S Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S194-8. PubMed ID: 8453697 [TBL] [Abstract][Full Text] [Related]
5. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM; Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704 [TBL] [Abstract][Full Text] [Related]
7. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. Schütte J; Mouridsen HT; Steward W; Santoro A; van Oosterom AT; Somers R; Blackledge G; Verweij J; Dombernowsky P; Thomas D Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S204-9. PubMed ID: 8453699 [TBL] [Abstract][Full Text] [Related]
8. Ifosfamide combination regimens for soft-tissue sarcoma. Stuart-Harris R; Dalley D; Bell DR; Levi J; Simes RJ; Wiltshaw E Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S185-8. PubMed ID: 8453695 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644 [TBL] [Abstract][Full Text] [Related]
10. Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. Toma S; Palumbo R; Canavese G; Albanese E; Cantoni E; Barisone A; Reggiardo G; Rosso R; Santi L Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S222-7. PubMed ID: 8453703 [TBL] [Abstract][Full Text] [Related]
11. Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide. Weh HJ; Agarwal K; Zornig C; Schwarz R; Dietel M; Hossfeld DK Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S189-93. PubMed ID: 8453696 [TBL] [Abstract][Full Text] [Related]
12. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT; Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336 [TBL] [Abstract][Full Text] [Related]
13. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112 [TBL] [Abstract][Full Text] [Related]
14. A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults. Harstrick A; Bokemeyer C; Schmoll HJ; Köhne-Wömpner CH; Knipp H; Schöffski P; Anagnou J; Wipperman B; Neumann S; Poliwoda H Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S217-21. PubMed ID: 8453702 [TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. Edmonson JH; Ryan LM; Blum RH; Brooks JS; Shiraki M; Frytak S; Parkinson DR J Clin Oncol; 1993 Jul; 11(7):1269-75. PubMed ID: 8315424 [TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy of soft tissue sarcoma in adults]. Rouëssé J; Spielmann M; Le Chevalier T; Tubiana-Hulin M; Tursz T Bull Acad Natl Med; 1991 Nov; 175(8):1251-9; discussion 1259-60. PubMed ID: 1809496 [TBL] [Abstract][Full Text] [Related]
17. The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. Steward WP; Verweij J; Somers R; Spooner D; Kerbrat P; Clavel M; Crowther D; Rouesse J; Tursz T; Tueni E Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S241-4. PubMed ID: 8453707 [TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G; J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977 [TBL] [Abstract][Full Text] [Related]
19. The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. Pápai Z; Bodoky G; Szántó J; Poller I; Rahóty P; Eckhardt S; Láng I; Szendroi M Cancer; 2000 Jul; 89(1):177-80. PubMed ID: 10897015 [TBL] [Abstract][Full Text] [Related]
20. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]